View Future GrowthSunny Pharmtech 과거 순이익 실적과거 기준 점검 0/6Sunny Pharmtech 의 수입은 연평균 -10.4%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 9.9%의 비율로 증가했습니다. 매출은 연평균 1.9%의 비율로 증가해 왔습니다.핵심 정보-10.37%순이익 성장률-6.75%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률18.53%매출 성장률1.94%자기자본이익률-40.01%순이익률-119.38%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Apr 27Full year 2024 earnings released: NT$1.05 loss per share (vs NT$0.44 loss in FY 2023)Full year 2024 results: NT$1.05 loss per share (further deteriorated from NT$0.44 loss in FY 2023). Revenue: NT$418.0m (down 2.5% from FY 2023). Net loss: NT$156.0m (loss widened 146% from FY 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 18Full year 2023 earnings released: NT$0.44 loss per share (vs NT$1.23 loss in FY 2022)Full year 2023 results: NT$0.44 loss per share (improved from NT$1.23 loss in FY 2022). Revenue: NT$428.8m (up 19% from FY 2022). Net loss: NT$63.3m (loss narrowed 63% from FY 2022).Reported Earnings • Aug 15First half 2023 earnings released: NT$0.38 loss per share (vs NT$0.77 loss in 1H 2022)First half 2023 results: NT$0.38 loss per share (improved from NT$0.77 loss in 1H 2022). Revenue: NT$177.4m (up 14% from 1H 2022). Net loss: NT$52.1m (loss narrowed 51% from 1H 2022).Reported Earnings • Apr 12Full year 2022 earnings released: NT$1.23 loss per share (vs NT$1.31 loss in FY 2021)Full year 2022 results: NT$1.23 loss per share (improved from NT$1.31 loss in FY 2021). Revenue: NT$359.6m (up 49% from FY 2021). Net loss: NT$170.2m (loss narrowed 2.6% from FY 2021).Reported Earnings • Aug 15First half 2022 earnings released: NT$0.77 loss per share (vs NT$0.76 loss in 1H 2021)First half 2022 results: NT$0.77 loss per share (down from NT$0.76 loss in 1H 2021). Revenue: NT$155.4m (up 27% from 1H 2021). Net loss: NT$106.4m (loss widened 7.5% from 1H 2021).모든 업데이트 보기Recent updates공시 • Mar 23Sunny Pharmtech Inc., Annual General Meeting, Jun 26, 2026Sunny Pharmtech Inc., Annual General Meeting, Jun 26, 2026. Location: 4 floor building. o no,255, lung yuan 1st rd., longtan district, taoyuan city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$153m free cash flow). Earnings have declined by 2.5% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (NT$2.75b market cap, or US$87.3m).New Risk • Jan 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$153m free cash flow). Earnings have declined by 2.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (NT$2.53b market cap, or US$80.1m).Reported Earnings • Apr 27Full year 2024 earnings released: NT$1.05 loss per share (vs NT$0.44 loss in FY 2023)Full year 2024 results: NT$1.05 loss per share (further deteriorated from NT$0.44 loss in FY 2023). Revenue: NT$418.0m (down 2.5% from FY 2023). Net loss: NT$156.0m (loss widened 146% from FY 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$2.13b market cap, or US$64.6m).공시 • Mar 28Sunny Pharmtech Inc., Annual General Meeting, Jun 16, 2025Sunny Pharmtech Inc., Annual General Meeting, Jun 16, 2025. Location: 4 floor building. o no,255, lung yuan 1st rd., longtan district, taoyuan city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.6m).New Risk • Nov 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.25b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risk Market cap is less than US$100m (NT$3.25b market cap, or US$99.7m).New Risk • Aug 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$112m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).New Risk • Jul 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).Reported Earnings • Apr 18Full year 2023 earnings released: NT$0.44 loss per share (vs NT$1.23 loss in FY 2022)Full year 2023 results: NT$0.44 loss per share (improved from NT$1.23 loss in FY 2022). Revenue: NT$428.8m (up 19% from FY 2022). Net loss: NT$63.3m (loss narrowed 63% from FY 2022).공시 • Apr 04Sunny Pharmtech Inc., Annual General Meeting, Jun 27, 2024Sunny Pharmtech Inc., Annual General Meeting, Jun 27, 2024.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).New Risk • Oct 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risk Shareholders have been diluted in the past year (7.2% increase in shares outstanding).New Risk • Sep 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).Reported Earnings • Aug 15First half 2023 earnings released: NT$0.38 loss per share (vs NT$0.77 loss in 1H 2022)First half 2023 results: NT$0.38 loss per share (improved from NT$0.77 loss in 1H 2022). Revenue: NT$177.4m (up 14% from 1H 2022). Net loss: NT$52.1m (loss narrowed 51% from 1H 2022).Reported Earnings • Apr 12Full year 2022 earnings released: NT$1.23 loss per share (vs NT$1.31 loss in FY 2021)Full year 2022 results: NT$1.23 loss per share (improved from NT$1.31 loss in FY 2021). Revenue: NT$359.6m (up 49% from FY 2021). Net loss: NT$170.2m (loss narrowed 2.6% from FY 2021).Reported Earnings • Aug 15First half 2022 earnings released: NT$0.77 loss per share (vs NT$0.76 loss in 1H 2021)First half 2022 results: NT$0.77 loss per share (down from NT$0.76 loss in 1H 2021). Revenue: NT$155.4m (up 27% from 1H 2021). Net loss: NT$106.4m (loss widened 7.5% from 1H 2021).공시 • Apr 04Sunny Pharmtech Inc., Annual General Meeting, Jun 30, 2022Sunny Pharmtech Inc., Annual General Meeting, Jun 30, 2022.매출 및 비용 세부 내역Sunny Pharmtech가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TPEX:6676 매출, 비용 및 순이익 (TWD Millions)날짜매출순이익일반관리비연구개발비31 Dec 25253-30216422730 Sep 25272-28617122930 Jun 25290-27017823131 Mar 25354-21317422531 Dec 24418-15617021930 Sep 24452-10316220730 Jun 24485-5015319531 Mar 24457-5715120231 Dec 23429-6314920930 Sep 23405-9014722430 Jun 23382-11614524031 Mar 23371-14314224831 Dec 22360-17013825630 Sep 22317-17613622630 Jun 22274-18213319731 Mar 22257-17912718431 Dec 21241-17512017130 Sep 21277-16211717530 Jun 21312-15011317831 Mar 21366-12611518031 Dec 20420-10211618230 Sep 20426-11211418730 Jun 20432-12111119231 Mar 20333-17410719931 Dec 19234-22610420630 Sep 19194-26010325130 Jun 19153-29510329631 Mar 19148-29711130131 Dec 18143-30011930530 Sep 1886-30211925830 Jun 1830-30411821131 Mar 1826-28710619431 Dec 1722-2699317730 Sep 1718-2568017730 Jun 1715-2436717631 Mar 1720-2355918631 Dec 1624-2275119631 Dec 1515-14639122양질의 수익: 6676 은(는) 현재 수익성이 없습니다.이익 마진 증가: 6676는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 6676은 수익성이 없으며 지난 5년 동안 손실이 연평균 10.4% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 6676의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 6676은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 6676는 현재 수익성이 없으므로 자본 수익률이 음수(-40.01%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/26 20:23종가2026/06/26 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sunny Pharmtech Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Apr 27Full year 2024 earnings released: NT$1.05 loss per share (vs NT$0.44 loss in FY 2023)Full year 2024 results: NT$1.05 loss per share (further deteriorated from NT$0.44 loss in FY 2023). Revenue: NT$418.0m (down 2.5% from FY 2023). Net loss: NT$156.0m (loss widened 146% from FY 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 18Full year 2023 earnings released: NT$0.44 loss per share (vs NT$1.23 loss in FY 2022)Full year 2023 results: NT$0.44 loss per share (improved from NT$1.23 loss in FY 2022). Revenue: NT$428.8m (up 19% from FY 2022). Net loss: NT$63.3m (loss narrowed 63% from FY 2022).
Reported Earnings • Aug 15First half 2023 earnings released: NT$0.38 loss per share (vs NT$0.77 loss in 1H 2022)First half 2023 results: NT$0.38 loss per share (improved from NT$0.77 loss in 1H 2022). Revenue: NT$177.4m (up 14% from 1H 2022). Net loss: NT$52.1m (loss narrowed 51% from 1H 2022).
Reported Earnings • Apr 12Full year 2022 earnings released: NT$1.23 loss per share (vs NT$1.31 loss in FY 2021)Full year 2022 results: NT$1.23 loss per share (improved from NT$1.31 loss in FY 2021). Revenue: NT$359.6m (up 49% from FY 2021). Net loss: NT$170.2m (loss narrowed 2.6% from FY 2021).
Reported Earnings • Aug 15First half 2022 earnings released: NT$0.77 loss per share (vs NT$0.76 loss in 1H 2021)First half 2022 results: NT$0.77 loss per share (down from NT$0.76 loss in 1H 2021). Revenue: NT$155.4m (up 27% from 1H 2021). Net loss: NT$106.4m (loss widened 7.5% from 1H 2021).
공시 • Mar 23Sunny Pharmtech Inc., Annual General Meeting, Jun 26, 2026Sunny Pharmtech Inc., Annual General Meeting, Jun 26, 2026. Location: 4 floor building. o no,255, lung yuan 1st rd., longtan district, taoyuan city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$153m free cash flow). Earnings have declined by 2.5% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (NT$2.75b market cap, or US$87.3m).
New Risk • Jan 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$153m free cash flow). Earnings have declined by 2.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (NT$2.53b market cap, or US$80.1m).
Reported Earnings • Apr 27Full year 2024 earnings released: NT$1.05 loss per share (vs NT$0.44 loss in FY 2023)Full year 2024 results: NT$1.05 loss per share (further deteriorated from NT$0.44 loss in FY 2023). Revenue: NT$418.0m (down 2.5% from FY 2023). Net loss: NT$156.0m (loss widened 146% from FY 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$2.13b market cap, or US$64.6m).
공시 • Mar 28Sunny Pharmtech Inc., Annual General Meeting, Jun 16, 2025Sunny Pharmtech Inc., Annual General Meeting, Jun 16, 2025. Location: 4 floor building. o no,255, lung yuan 1st rd., longtan district, taoyuan city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.6m).
New Risk • Nov 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.25b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risk Market cap is less than US$100m (NT$3.25b market cap, or US$99.7m).
New Risk • Aug 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$112m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
New Risk • Jul 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
Reported Earnings • Apr 18Full year 2023 earnings released: NT$0.44 loss per share (vs NT$1.23 loss in FY 2022)Full year 2023 results: NT$0.44 loss per share (improved from NT$1.23 loss in FY 2022). Revenue: NT$428.8m (up 19% from FY 2022). Net loss: NT$63.3m (loss narrowed 63% from FY 2022).
공시 • Apr 04Sunny Pharmtech Inc., Annual General Meeting, Jun 27, 2024Sunny Pharmtech Inc., Annual General Meeting, Jun 27, 2024.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
New Risk • Oct 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risk Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
New Risk • Sep 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
Reported Earnings • Aug 15First half 2023 earnings released: NT$0.38 loss per share (vs NT$0.77 loss in 1H 2022)First half 2023 results: NT$0.38 loss per share (improved from NT$0.77 loss in 1H 2022). Revenue: NT$177.4m (up 14% from 1H 2022). Net loss: NT$52.1m (loss narrowed 51% from 1H 2022).
Reported Earnings • Apr 12Full year 2022 earnings released: NT$1.23 loss per share (vs NT$1.31 loss in FY 2021)Full year 2022 results: NT$1.23 loss per share (improved from NT$1.31 loss in FY 2021). Revenue: NT$359.6m (up 49% from FY 2021). Net loss: NT$170.2m (loss narrowed 2.6% from FY 2021).
Reported Earnings • Aug 15First half 2022 earnings released: NT$0.77 loss per share (vs NT$0.76 loss in 1H 2021)First half 2022 results: NT$0.77 loss per share (down from NT$0.76 loss in 1H 2021). Revenue: NT$155.4m (up 27% from 1H 2021). Net loss: NT$106.4m (loss widened 7.5% from 1H 2021).
공시 • Apr 04Sunny Pharmtech Inc., Annual General Meeting, Jun 30, 2022Sunny Pharmtech Inc., Annual General Meeting, Jun 30, 2022.